SCHEMBL13966261

SCHEMBL13966261

CC(C)Oc1nc2ccccc2c2cc(F)ccc12

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.47
▸ ATM Q13315 3/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ PKM P14618 1/20 0.40
▸ HTR4 Q13639 1/20 0.39
▸ BTK Q06187 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HCRTR1 O43613 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TLR8 Q9NR97 1/20 0.37
▸ GLA P06280 1/20 0.36
▸ TRPA1 O75762 1/20 0.36
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13966264 0.94 MAPT (0.47) MAPTATML3MBTL1TSHRKDM4E
SCHEMBL13966260 0.90 HTR4 (0.47) MAPTATML3MBTL1TSHRKDM4E
SCHEMBL13966262 0.89 HTR4 (0.39) MAPTATML3MBTL1TSHRCYP1A2
SCHEMBL13966259 0.84 ATM (0.56) MAPTATML3MBTL1TSHRKDM4E
SCHEMBL13966274 0.84 MAPT (0.48) MAPTATML3MBTL1TSHRKDM4E
SCHEMBL13975766 0.83 PKM (0.48) MAPTL3MBTL1KDM4ECYP1A2CYP2C9
SCHEMBL13966272 0.82 TRPA1 (0.44) MAPTATMKDM4EMEN1KMT2A
SCHEMBL13966273 0.81 HTR4 (0.36) MAPTATMKDM4EPKMHTR4
SCHEMBL13966277 0.79 TRPV4 (0.39) CYP1A2CYP2C9PKMTRPA1LMNA
SCHEMBL13966377 0.78 KIF11 (0.38) MAPTATML3MBTL1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8951964-B2 Phenanthridine macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2015-02-10 — — US disclosed
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2012-11-22 — — US disclosed
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2012-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS TMPRSS15, HPN, PRSS1 MAPT 3503/4885ATM 4349/4885L3MBTL1 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback